Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Posted: 31 January 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase…
New tool can detect fast-spreading SARS-COV-2 variants before they take off
Posted: 31 January 2025 Researchers have developed a powerful tool that can detect variants of SARS-CoV-2 with high transmission potential before they become widespread. This approach could significantly support public health efforts to control outbreaks and help identify…
Professor Tony Haymet Australia’s new Chief Scientist
Posted: 29 January 2025 A world-leading oceanographer, chemist and entrepreneur has been appointed Australia’s next Chief Scientist. Emeritus Professor Tony Haymet will become Australia’s tenth Chief Scientist, taking over from Dr Cathy Foley who recently finished her term.…
Solving Critical Neonatal Challenges with a Design-Led Solution that Reduces Risks and Saves Lives
Posted: 28 January D+I Part of Capgemini (D+I) for Navi Medical Technologies Design can change lives. And when those lives are tiny, the impact is even greater. The Head of D+I Part of Capgemini Melbourne (D+I) – Rod Wiebenga has…
DoD to conduct Paid CT:VQ Pilot Ahead of FDA Submission
Posted: 28 January 2025 4DMedical has won a contract with the United States Department of Defense (DoD) to pilot its CT Ventilation-Perfusion (CT:VQ™) technology to assess lung health in a fixed cohort of active duty personnel. This contract…
New Grants Program Boosting Women’s Health Research
Posted: 28 January 2025 For decades, research into health has left women out – because women were seen as too unreliable to participate due to menstruation and hormonal fluctuations. Now, the Allan Labor Government is bridging this gap,…
ProBio Congratulates GeneCraft on MFDS Clearance for RX001, the World’s First AAV-Based Lung Cancer Therapy
Posted: 24 January 2025 Recently, GeneCraft, a partner of ProBio, announced that its gene therapy for non-small cell lung cancer (NSCLC), RX001, has received IND clearance from the Ministry of Food and Drug Safety (MFDS) in South Korea.…
Melbourne/Malawi collaboration to explore using new on-the-spot syphilis diagnosis tool for at-risk mothers in Africa
Posted: 15 January 2025 A team from the University of Melbourne will travel to Malawi next year to work with colleagues from the Kamuzu University of Health Sciences (KUHeS) to field test and work towards implementation of a…
Australia’s first mRNA vaccine candidate addresses COVID ‘immune imprinting’
Posted: 15 January 2025 The team of scientists behind Australia’s first mRNA COVID-19 vaccine have published a new study demonstrating the vaccine’s ability to overcome the issue of ‘immune imprinting.’ Immune imprinting occurs when exposure to one virus…
Shaping The Future Of Our Medical Research Workforce
Posted: 15 January 2025 The Allan Labor Government is supporting the state’s medical researchers to drive the next generation of medical breakthroughs with a new Workforce Action Plan. Minister for Medical Research Ben Carroll this week launched Victoria’s Health and Medical…
Completion of Genetype Risk Assessment Portfolio Acquisition
Posted: 15 January 2025 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) advises that it has completed the acquisition of select Australian and US assets related to the Genetype Business from…
DMX-200 FSGS ACTION3 PHASE 3 TRIAL PART 2 RECRUITMENT COMPLETE
Posted: 15 January 2025 Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, today confirmed that the first 144 patients have been randomised in its DMX 200 ACTION3 Phase 3 clinical trial in…
